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Abstract 
In this edition of the Huntington’s Disease Clinical Trials Corner we expand on the 
HD-DBS and on the TRIHEP3 trials, and we list all currently registered and ongoing 
clinical trials in Huntington’s disease.  
Main text 
INTRODUCTION 
The Huntington’s Disease Clinical Trials Corner is a regular section devoted to 
highlighting ongoing and recently completed clinical trials in Huntington’s disease 
(HD). Clinical trials previously reviewed by the Huntington’s Disease Clinical Trials 
Corner are listed in table 1. 
 
[table 1] 
 
In this edition, we highlight the HD-DBS trial (NCT02535884)(1), and the TRIPHEP3 
trial (NCT02453061)(2). We tabulate all currently registered and ongoing clinical 
trials in tables 2 to 4. For further details on the methodology used, please refer to the 
first edition of Huntington’s Disease Clinical Trials Corner(3). 
If you would like to draw attention to specific trials, please feel free to email us at: 
f.rodrigues@ucl.ac.uk and e.wild@ucl.ac.uk. 
 
In addition to the above, the published report of the IONIS-HTTRx trial 
(NCT02519036) is worthy of mention. The paper reports that monthly intrathecal 
IONIS-HTTRx/RG6042 – an antisense oligonucleotide that signals wild-type and 
mutant huntingtin pre-mRNA to be degraded by RNase H1 – was safe and well-
tolerated, and produced dose-dependent reductions in cerebrospinal fluid mutant 
huntingtin in early HD patients (4). This is an interesting signal but caution should be 
exercised as to whether this reduction translates into a clinically significant benefit for 
people with HD. Further investigation into the effects of this drug are expected from 
the currently ongoing phase 3 GENERATION-HD1 trial (NCT03761849)(5) and 
associated studies(6-10). These studies will help us better characterize the safety 
profile of this compound, define the most efficient posology, and understand if it is 
associated with a clinically relevant benefit, and towards which disease domain.  
ONGOING CLINICAL TRIALS 
A list of all ongoing clinical trials is given in Tables 2, 3 and 4. 
 
HD-DBS (NCT02535884) 
Study title: Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's 
Disease (HD) (HD-DBS)(1). 
Intervention: DBS of the GP (11) with Medtronic ACTIVA® PC neurostimulator 
(Model 37601). 
Description: The HD-DBS trial, sponsored by Heinrich-Heine University, aims to 
evaluate the efficacy and safety of pallidal DBS in adults (18 or more years of age) 
with manifest HD (i.e. clinically symptomatic and genetically confirmed [CAG ≥ 36]) 
and moderate disease stage (defined by the investigators as an Unified Huntington’s 
Disease Rating Scale [UHDRS] total motor score [TMS] ≥ 30), chorea (UHDRS 
chorea score ≥ 10) and a Mattis Dementia Rating Scale ≥ 120, comparing with sham 
stimulation, for motor function.  
People with juvenile or predominantly bradykinetic forms of the disease, postural 
instability, unstable medication in the 6 weeks previous to inclusion, unstable 
medical or psychiatric comorbidities, coagulopathies and/or increased risk of 
haemorrhage, implanted pacemaker or defibrillator, pregnant or breast-feeding are 
not eligible for this study.  
This trial is an international, multi-centre, randomized, sham-controlled, double-blind, 
parallel study. It will have 2 study arms: the stimulation group, where participants will 
be turned on stimulation immediately after implantation of the stimulator; and the 
sham stimulation group, where participants will be implanted a stimulator but it will 
not be switched on. The study will last 12 weeks, and after that period all 
participants’ stimulators will be turned on. 
The trial has already started recruitment, and has a recruitment target of 50 
participants, over 4 countries (Austria, France, Germany and Switzerland) and 12 
sites. 
The primary outcome will be the UHDRS TMS at 12 weeks, measured as the 
difference in the mean change from baseline line between the stimulation arm and 
the sham-stimulation arm. The secondary outcomes will include the UHDRS chorea 
score and the bradykinesia items, the Burke-Fahn-Marsden Dystonia Rating Scale, 
the Q-Motor choreomotography task, the Mattis Dementia Rating Scale, the Verbal 
Fluency Test, the Symbol Digits Modalities Test, the Stroop Test, the Hospital 
Anxiety and Depression Scales and the Snaith Irritability Scale, the Problem 
Behaviours Assessment Short Form, the Short Form 36 Health Survey, the Clinical 
Global Impression Scale, and safety.  
Sponsors/funders: Heinrich-Heine University, KKS Netzwerk, Medtronic, the George 
Huntington Institute, EHDN and CHDI Foundation. 
Comments:  
DBS is a relatively well-studied intervention for some manifestations of Parkinson’s 
disease, tremor and dystonia. . DBS involves the surgical implantation of electrical 
electrodes in the deep brain structures, connected via a wire to an implantable pulse 
generator (i.e. stimulator) usually positioned subcutaneously in the pectoral region. 
Although the precise mechanisms of action are still not completely understood, this 
intervention is aimed at interrupting certain neuronal circuits.  
In Parkinson’s disease DBS is frequently used to minimized levodopa-induced 
dyskinesia, which frequently have a close phenomenology to chorea in HD, but a 
different aetiology. This is accomplished by better controlling the cardinal features of 
PD, hence reducing the levodopa dose equivalents. There is still uncertainty about 
whether there is a direct effect of DBS over dyskinesia. In HD, chorea is thought to 
be caused by the loss of striatal projections to the indirect basal ganglia pathway and 
consequent thalamic overactivity(11), and although there is a shortage of good-
quality evidence, some pilot studies have shown interesting preliminary results when 
manipulating these circuits with DBS in HD(12, 13).  
The scarcity of data so far accumulated precludes drawing conclusions on the safety 
and efficacy profile of this intervention in HD, but it seems sensible to assume that 
this population may be susceptible from the same intervention-related adverse 
events as other tested populations. Disease-specific side effects may be more 
difficult to predict.  
Only large international, multicentric, prospective controlled studies will allow us to 
fully understand the efficacy and safety profile of DBS in HD.  
 
TRIPHEP3 (NCT02453061) 
Study title: A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an 
Anaplerotic Therapy in Huntington's Disease (TRIHEP3)(2). 
Intervention: Triheptanoin oil 1 g/kg/day(14). 
Description: The TRIPHEP3 trial, sponsored by the Institut National de la Santé et de 
la Recherche Médicale and Ultragenyx Pharmaceutical Inc., aims to evaluate the 
effects of daily triheptanoin in adults (≥18 years of age) with genetically confirmed 
manifest HD (i.e. UHDRS TMS between 5 and 40), compared with daily safflower oil. 
People with a BMI < 18 or > 30, hypersensitivity to triheptanoin, major co-morbidities, 
history of severe head injury, pregnant or breast-feeding, or on tetrabenazine were 
not eligible. 
TRIPHEP3 is an international, multi-centre, randomized, double-blind, controlled, 
parallel phase 2 trial. It has 2 study arms: the active group, where participants will 
receive triheptanoin oil 1 g/kg/day for 12 months; and the comparator group, where 
participants will receive safflower oil 1 g/kg/day for 6 months and triheptanoin oil 1 
g/kg/day for the following 6 months.  
The study will last 12 months, the first half over double-blinded conditions, and the 
second half as an open-label extension. Recruitment is currently closed and was led 
by one centre in France and one centre in the Netherlands. One hundred 
participants were recruited. 
The primary outcomes are pharmacodynamics neuroimaging markers at 3 and 6 
months - 31P-MRS and volumetric MRI. Secondary outcomes include the UHDRS, 
comprising the motor, functional and cognitive components, the Problem Behaviours 
Assessment Short Form, the Short Form 36 Health Survey, adverse events, 
tolerance and other neuroimaging biomarkers. 
Sponsors/funders: Institut National de la Santé et de la Recherche Médicale and 
Ultragenyx Pharmaceutical Inc. 
Comments:  
 
Albeit with a low success rate(15), several dietary nutrients with possible effects over 
metabolic processes have been tested in HD over the years, including d-α-
tocopherol(16), idebenone(17), co-enzyme Q10(18), ethyl-eicosapentaenoate(19-
21), and creatine(22-24).  
Triheptanoin is an odd-chain triglyceride with anaplerotic properties (i.e. it 
replenishes biochemical cycles with intermediate metabolites), providing the Krebs 
cycle with both acetyl-CoA and propionyl-CoA. So far, triheptanoin has been tested 
for several disorders of the brain metabolism, including pyruvate decarboxylase 
deficiency, and GLUT1 deficiency where a significant symptomatic effect was 
demonstrated in a small open-label study(25).  
In HD, several lines of evidence support the existence of a dysfunction of the energy 
metabolism, including the Krebs cycle, oxidative phosphorylation and glycolysis. Two 
small open-label studies in HD showed that triheptanoin may have the potential to 
bring peripheral(26) and central nervous system metabolic biomarkers(27) to levels 
observed in healthy controls. They also anticipate triheptanoin to be well 
tolerated(26, 27), and overall the cumulative evidence suggests a good safety profile 
for doses between 1 to 2.5 g/kg/day(14). 
The TRIPHEP3 trial will be completed by the end of 2019 and the results are 
expected in mid-2020. 
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Tables 
Table 1 
Table 1 – Clinical trials previously reviewed by the Huntington’s Disease Clinical 
Trials Corner. *IONIS-HTTRx, and RG6042 refer to the same molecule. 
  Trial name Intervention Edition 
NCT02519036 IONIS-HTTRx IONIS-HTTRx* 
September 2017(3) 
NCT02215616 LEGATO-HD Laquinimod 
NCT02197130 Amaryllis PF-02545920 
NCT02006472 PRIDE-HD Pridopidine 
NCT03225833 PRECISION-HD1 WVE-120101 
February 2018(28) NCT03225846 PRECISION-HD2 WVE-120102 
NCT01795859 FIRST-HD Deutetrabenazine 
NCT02481674 SIGNAL VX15/2503 
August 2018(29) 
NCT00712426 CREST-E Creatine 
NCT03761849 GENERATION-HD1 RG6042* 
January 2019(30) 
NCT03344601  PACE-HD Physical activity 
NCT02535884 HD-DBS Deep brain stimulation 
June 2019 
NCT02453061 TRIHEP3 Triheptanoin 
 
Table 2 
Table 2 – Ongoing pharmacological clinical trials registered at the World Health Organization (WHO) International Clinical Trials 
Research Platform (ICTRP) for people with Huntington’s disease (HD). N/S, not specified; PD, Parkinson’s disease; VMAT2, 
Vesicular Monoamine Transporter 2. Note: IONIS-HTTRx, ISIS 443139 and RG6042 refer to the same molecule. New trials since 
the last Clinical Trials Corner are indicated by *. 
Registration ID Trial name Intervention 
Mechanism of Action 
Population Comparison Main outcome Study design 
Estimated 
Enrolment 
Sponsor Location 
NCT03854019* - 
Dextromethorphan
/quinidine 
Morphinan/class I 
antiarrhythmic agent 
HD with irritability Placebo 
Clinical efficacy at 6 
and 13 weeks 
Randomized, 
double-blind, 
placebo-
controlled, 
cross-over trial 
22 
University of 
Texas Health 
Science Center, 
Cures Within 
Reach 
USA 
(single centre) 
NCT03842969* GEN-EXTEND RG6042 
Allele-  
nonselective antisense 
oligonucleotide 
HD None 
Safety and 
tolerability at up to 5 
years 
Open-label 
extension 
950 
Hoffmann-La 
Roche 
USA, Canada, 
Europe  
(multi centre) 
NCT03761849 GENERATION-HD1 RG6042 
Allele-  
nonselective antisense 
oligonucleotide 
HD Placebo 
Clinical efficacy at 
101 weeks 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel trial 
660 
Hoffmann-La 
Roche 
USA, Canada, 
Europe  
(multi centre) 
NCT03787758 - SAGE-718 
NMDA positive 
allosteric modulator 
HD Placebo Safety at 21 days 
Randomized, 
double-blind, 
placebo-
controlled, 
multiple 
ascending 
dose trial 
10 
Sage 
Therapeutics 
N/S 
NCT03575676 - SOM3355 
VMAT2 inhibitor and 
β1 antagonist 
Early and 
moderate HD with 
chorea 
Placebo Chorea at 6 months 
Randomized, 
double-blind, 
placebo-
controlled, 
cross-over trial 
30 SOM Biotech SL 
Spain  
(multi centre) 
NCT03515213 - Fenofibrate PPARα agonist HD Placebo 
Pharmacodynamics 
at 6 months 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel trial 
20 
University of 
California, Irvine 
USA 
(single centre) 
NCT03764215 Tasigna HD Nilotinib 
Selective Bcr-Abl 
tyrosine kinase 
inihbitor 
HD None 
Safety, tolerability 
and 
pharmacodynamics 
at 3 months 
Open label, 
multiple 
ascending 
dose 
20 
Georgetown 
University 
USA 
(single centre) 
NCT03342053 IONIS-HTTRX OLE ISIS 443139 
Allele-  
nonselective antisense 
oligonucleotide 
HD None 
Safety and 
tolerability at 74 
weeks 
Open label 
extension 
46 
Ionis 
Pharmaceuticals 
Inc. 
Canada, 
Germany and 
UK  
(multi-centre) 
NCT03225833 PRECISION-HD1 WVE-120102 
Allele-selective 
antisense 
oligonucleotide 
HD Placebo 
Safety and 
tolerability at 1 and 
120 days 
Randomized, 
double-blind, 
placebo-
controlled, 
combined 
single 
ascending 
dose/multiple 
ascending 
dose trial 
48 
Wave Life 
Sciences Ltd. 
Canada and 
Poland 
(multi-centre) 
NCT03225846 PRECISION-HD2 WVE-120102 
Allele-selective 
antisense 
oligonucleotide 
HD Placebo 
Safety and 
tolerability at 1 and 
120 days 
Randomized, 
double-blind, 
placebo-
controlled, 
combined 
single 
ascending 
dose/multiple 
ascending 
dose trial 
48 
Wave Life 
Sciences Ltd. 
Canada and 
Poland 
(multi-centre) 
NCT02453061 TRIHEP 3 Triheptanoin Anaplerotic therapy HD Safflower oil 
Pharmacodynamic 
efficacy at 6 months 
Randomized, 
double-blind, 
100 
Institut National 
de la Santé Et 
de la Recherche 
France, 
Netherlands 
(multi centre) 
controlled, 
parallel trial 
Médicale, 
Ultragenyx 
Pharmaceutical 
Inc 
NCT02509793 
- 
 
Tetrabenazine VMAT2 inhibitor HD with impulsivity None 
Cognitive and 
behavioural effects 
at 8 weeks 
Single group, 
open-label trial 
20 
University of 
Texas Health 
Science Center, 
and H. 
Lundbeck A/S 
USA 
(single centre) 
NCT02481674 SIGNAL 
 
VX15/2503 
Anti-semaphorin 4D 
monoclonal antibody 
Late premanifest or 
early HD 
Placebo 
Safety and 
tolerability at 15 and 
21 months 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel trial 
240 
Vaccinex Inc., 
Huntington 
Study Group 
USA 
(multi centre) 
NCT02336633 REVHD Resveratrol Dietary supplement HD Placebo 
Neuroimaging 
biomarkers at 1 
year 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel trial 
102 
Assistance 
Publique - 
Hôpitaux de 
Paris 
France 
(multi centre) 
EUCTR2013-
002545-10-SE 
OSU6162Open1309 (-)-OSU616 
Monoaminergic 
stabilizer 
HD, PD, brain 
trauma, stroke, 
myalgic 
encephalomyelitis 
and narcolepsy 
None 
Safety at 3, 6 and 
12 months 
Single group, 
open-label trial 
240 
A. Carlsson 
Research AB 
Sweden 
(multi centre) 
NCT00514774 UDCA-HD Ursodiol Bile acid HD Placebo 
Safety, tolerability 
and 
pharmacokinetics at 
35 days 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel trial 
21 
Oregon Health 
and Science 
University, 
Huntington 
Study Group, 
Huntington 
Society of 
Canada 
N/S 
 
  
Table 3 
Table 3 – Ongoing invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International 
Clinical Trials Research Platform (ICTRP) for people with Huntington’s disease (HD). AD, Alzheimer’s disease, CBD; Corticobasal 
Degeneration; DBS, deep brain stimulation; ET, Essential Tremor; GP, Globus pallidus; HT, Holmes Tremor; MNC, mononuclear 
cells; MS, Multiple Sclerosis; PD, Parkinson’s disease; TD, Tardive dyskinesia; WD, Wilson’s disease. New trials since the last 
Clinical Trials Corner are indicated by *. 
Registration ID Trial name Intervention 
Mechanism 
of Action 
Population Comparison Main outcome Study design 
Esimated 
Enrolment 
Sponsor Location 
ISRCTN52651778 TRIDENT 
Foetal stem 
cell 
transplant 
Stem cell 
therapy 
Early stage 
HD 
Usal care 
Safety at 4 
weeks 
Randomized, 
open label, 
controlled, 
parallel trial 
30 
Cardiff 
University 
UK 
(single centre) 
NCT02728115 SAVE-DH Cellavita 
Stem cell 
therapy 
HD None Safety at 5 years 
Non-
randomized, 
open label, 
uncontrolled, 
parallel trial 
6 Azidus Brasil 
Brazil 
(single centre) 
NCT03252535 ADORE-HD Cellavita 
Stem cell 
therapy 
HD Placebo 
Efficacy at 120 
days 
Randomized, 
double-blind, 
placebo-
35 Azidus Brasil 
Brazil 
(single centre) 
controlled, 
parallel trial 
NCT03297177 - 
Autologous 
stem/stromal 
cells 
Autologous 
stem/stromal 
cell injection 
HD, AD, PD, 
CBD, MS 
None Safety at 5 years 
Single group, 
open-label trial 
300 
Healeon Medical 
Inc, Global 
Alliance for 
Regenerative 
Medicine, 
Regeneris 
Medical 
USA and 
Honduras 
(multi-centre) 
NCT02535884 HD-DBS GP DBS 
Deep brain 
stimulation 
Moderate 
HD with 
chorea 
Sham 
intervention 
Efficacy at 12 
months 
Randomized, 
double-blind, 
sham-
controlled, 
parallel trial 
50 
Heinrich-Heine 
University, KKS 
Netzwerk, 
Medtronic, The 
George Institute, 
EHDN, CHDI 
Foundation, Inc. 
 
Austria, France 
Germany, 
Switzerland 
(multi centre) 
NCT01834053 BMACHC 
Bone 
Marrow 
Derived 
MNC 
transplant 
Bone 
marrow 
transplant 
HD with 
chorea 
None 
Cognitive and 
behavioural 
effects at 6 
months 
Single group, 
open-label trial 
50 
Chaitanya 
Hospital, Pune 
India 
(single centre) 
NCT02263430 - GP DBS 
Deep brain 
stimulation 
HD with 
chorea 
Sham 
stimulation 
Efficacy at 12 
months 
Randomized, 
double-blind, 
8 
Beijing Pins 
Medical Co., Ltd, 
China 
(single centre) 
placebo-
controlled, 
parallel trial 
Beijing Tiantan 
Hospital 
NCT02252380 - 
Magnetic 
Resonance 
Guided 
Focused 
Ultrasound 
Extracranial 
stereotactic 
radioablation 
HD, ET, HT, 
PD, WD, 
dystonia, 
TD, or 
orofacial 
dyskinesias 
None 
Adverse events 
after the 
procedure 
Single group, 
open-label trial 
10 InSightec 
Canada 
(single centre) 
  
Table 4 
Table 4– Ongoing non-invasive non-pharmacological clinical trials registered at the World Health Organization (WHO) International 
Clinical Trials Research Platform (ICTRP) for people with Huntington’s disease (HD). AD, Alzheimer’s disease; ALS, Amyotrophic 
Lateral Sclerosis; ET, Essential Tremor; HT, Holmes Tremor; MS, Multiple Sclerosis; PD, Parkinson’s disease; TD, Tardive 
dyskinesia. New trials since the last Clinical Trials Corner are indicated by *. 
Registration ID Trial name Intervention 
Mechanism of 
Action 
Population Comparison Main outcome Study design 
Esimated 
Enrolment 
Sponsor Location 
ACTRN126180
01717246 
- 
Multidisciplinary 
therapy program 
Exercise, 
cognitive 
training, lifestyle 
guidance and 
social activities 
Premanifest
HD 
Standard of 
care 
Feasability and 
safety 
Clustered, 
non-
randomized, 
open label, 
parallel trial 
40 
Edith Cowan 
University, 
Deakin 
University and 
Lotterywest 
Australia 
(two centres) 
NCT03417583 - 
Neuropsychiatric 
treatment protocol 
Multidisciplinary 
intervention 
HD with 
neuropsychi
atric 
symptoms 
Standard of 
care 
Change in 
quality of life at 
18 months 
Non-
randomized, 
assessor-
blinded, 
parallel trial 
100 
Vanderbilt 
University 
Medical Center 
and Teva 
Pharmaceuticals 
USA 
USA 
(single centre) 
CTRI/2018/01/0
11359 
- 
Repetitive 
transcranial 
Transcranial 
magnetic 
stimulation 
Early to 
moderate 
HD and PD 
Sham 
stimulation 
Efficacy at 5 
days 
Randomized, 
single-blind, 
placebo-
40 Vinay Goyal 
India 
(single centre) 
magnetic 
stimulation 
controlled, 
parallel trial 
NCT03344601 PACE-HD 
Supported 
structured aerobic 
exercise training 
program 
Physiotherapy HD 
Activity as 
usual 
Data 
completeness, 
recruitment, 
retention, safety, 
adherence, 
fidelity and 
acceptability at 
12 months  
Nested open-
label, 
randomized 
controlled 
parallel trial 
120 
Cardiff 
University and 
CHDI 
Foundation, Inc 
Germany, Spain 
and USA 
(multi centre) 
ACTRN126170
01269325 
- 
Swallowing skill 
training 
Speech and 
language 
therapy 
HD and ALS None 
Swallowing 
function and 
quality of life at 2 
weeks 
Single group, 
open-label trial 
54 
University of 
Canterbury 
New Zealand 
(single centre) 
NCT02216474 - tDCS 
Transcranial 
magnetic 
stimulation 
HD or 
Tourette 
Syndrome 
Sham 
stimulation 
Efficacy at 2 
weeks 
Randomized, 
double-blind, 
placebo-
controlled, 
cross-over trial 
100 
Birmingham and 
Solihull Mental 
Health NHS 
Foundation 
Trust, University 
of Birmingham 
UK 
(single centre) 
 
 
